Related Experiment Video
Updated: Apr 18, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis
Shannon M Reilly1, Maryam Ahmadian2, Brian F Zamarron3
1Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Abstract:
The search for effective treatments for obesity and its comorbidities is of prime importance. We previously identified IKK-ε and TBK1 as promising therapeutic targets for the treatment of obesity and associated insulin resistance. Here we show that acute inhibition of IKK-ε and TBK1 with amlexanox treatment increases cAMP levels in subcutaneous adipose depots of obese mice, promoting the synthesis and secretion of the cytokine IL-6 from adipocytes and preadipocytes, but not from macrophages. IL-6, in turn, stimulates the phosphorylation of hepatic Stat3 to suppress expression of genes involved in gluconeogenesis, in the process improving glucose handling in obese mice. Preliminary data in a small cohort of obese patients show a similar association. These data support an important role for a subcutaneous adipose tissue-liver axis in mediating the acute metabolic benefits of amlexanox on glucose metabolism, and point to a new therapeutic pathway for type 2 diabetes.
Insights
Amlexanox treatment for obesity increases cAMP, promoting IL-6 secretion from fat cells. This improves glucose metabolism in obese mice by affecting the liver, suggesting a new therapeutic pathway for type 2 diabetes.
Area of Science:
- Metabolic disease research
- Molecular mechanisms of obesity
- Diabetes therapeutics
Background:
- Obesity and associated insulin resistance necessitate novel therapeutic strategies.
- IKK-ε (inhibitor of κB kinase ε) and TBK1 (TANK-binding kinase 1) were previously identified as potential targets for obesity treatment.
- Understanding the molecular pathways linking obesity, insulin resistance, and glucose metabolism is crucial.
Purpose of the Study:
- To investigate the acute metabolic effects of amlexanox, an inhibitor of IKK-ε and TBK1, in obese mice.
- To elucidate the role of amlexanox in modulating cAMP levels, cytokine secretion, and hepatic gene expression.
- To explore the potential of targeting the adipose tissue-liver axis for treating metabolic dysfunction.
Main Methods:
- Administration of amlexanox to obese mice to inhibit IKK-ε and TBK1.
- Measurement of cyclic adenosine monophosphate (cAMP) levels in subcutaneous adipose tissue.
- Assessment of interleukin-6 (IL-6) synthesis and secretion from adipocytes and preadipocytes.
- Analysis of hepatic Stat3 phosphorylation and gene expression related to gluconeogenesis.
- Preliminary analysis of similar metabolic effects in a cohort of obese patients.
Main Results:
- Amlexanox treatment acutely increased cAMP levels in subcutaneous adipose depots of obese mice.
- This increase in cAMP promoted the synthesis and secretion of IL-6 from adipocytes and preadipocytes.
- IL-6 stimulated hepatic Stat3 phosphorylation, suppressing genes involved in gluconeogenesis.
- These molecular events led to improved glucose handling in obese mice.
- Preliminary human data suggested a similar association in obese patients.
Conclusions:
- Amlexanox exerts acute metabolic benefits on glucose metabolism through a subcutaneous adipose tissue-liver axis.
- The pathway involves amlexanox-induced increase in cAMP, IL-6 secretion, and subsequent hepatic gene regulation.
- These findings highlight a novel therapeutic avenue for type 2 diabetes and obesity-related metabolic disorders.
More Related Videos
06:35Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
Published on: April 5, 2024
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression
Regulation of Food Intake
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...